0001181431-12-007835.txt : 20120210 0001181431-12-007835.hdr.sgml : 20120210 20120210165222 ACCESSION NUMBER: 0001181431-12-007835 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120208 FILED AS OF DATE: 20120210 DATE AS OF CHANGE: 20120210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nicholson John CENTRAL INDEX KEY: 0001420766 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 12593691 MAIL ADDRESS: STREET 1: C/O NEKTAR THERAPEUTICS STREET 2: 201 INDUSTRIAL ROAD CITY: SAN CARLOS STATE: CA ZIP: 94070 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 4 1 rrd333745.xml ANNUAL EQUITY COMPENSATION X0304 4 2012-02-08 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001420766 Nicholson John C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 0 1 0 0 SVP & Chief Financial Officer Stock Option 7.21 2012-02-08 4 A 0 50000 7.21 A 2020-02-07 Common Stock 50000 50000 D Stock Option 7.21 2012-02-08 4 A 0 50000 7.21 A 2020-02-07 Common Stock 50000 50000 D This stock option vests on a monthly pro-rata basis over a period of four (4) years from the grant date (February 8, 2012). This stock option is subject to both time-based vesting and performance-based vesting conditions, both of which must be met before the shares subject to the option become vested and exerciseable. The time-based vesting is on a monthly pro-rata basis over a period of four (4) years from the grant date (February 8, 2012). The performance-based vesting condition will be met only if Nektar (or a licensee) files a new drug registration with the FDA or the European Medicines Agency for a significant drug candidate program including, without limitation, the following: (1) NKTR-118 (an oral peripherally-acting opioid antagonist); (2) NKTR-102 (a topoisomerase I inhibitor); (3) NKTR-061/Amikacin Inhale (a drug-device combination for an inhaled solution of amikacin); or (4) BAX-855 (a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein). Gil M. Labrucherie, Attorney-in-Fact 2012-02-10